Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a dutch compassionate use program

Additional Metadata
Keywords	Myeloma, Refractory, Relapse, Stem cell transplantation, Thalidomide resistance
Persistent URL	doi.org/10.3816/CLML.2010.n.020, hdl.handle.net/1765/83402
Journal	Clinical Lymphoma, Myeloma and Leukemia
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Kneppers, E., Lokhorst, H., Eeltink, C., Huls, G., Kersten, M. J., Koedam, J., Minnema, M., van Oers, M., Raymakers, R., Schaafsma, M., Vellenga, E., Wijermans, P., Wittebol, S., Sonneveld, P.& Zweegman, S. (2010). Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a dutch compassionate use program. Clinical Lymphoma, Myeloma and Leukemia, 10(2), 138–143.https://doi.org/10.3816/CLML.2010.n.020

Publication